Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Sadie Khwaja; Balasubrahmanyam Kumar; Carl Philpott; David P. Strachan

doi:10.1016/S0140-6736(19)31881-1

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Sadie Khwaja, Balasubrahmanyam Kumar, Carl Philpott, David P. Strachan

Research output: Other contribution

940 Citations (Scopus)

Original language	English
Type	Supplementary Materials
Media of output	pdf
Number of pages	56
DOIs	https://doi.org/10.1016/S0140-6736(19)31881-1
Publication status	Published - Nov 2019

Access to Document

10.1016/S0140-6736(19)31881-1

Cite this

@misc{a3db1c8d59b5421c91b74b582e29786a,

title = "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials",

author = "Sadie Khwaja and Balasubrahmanyam Kumar and Carl Philpott and Strachan, {David P.}",

year = "2019",

month = nov,

doi = "10.1016/S0140-6736(19)31881-1",

language = "English",

type = "Other",

}

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. / Khwaja, Sadie; Kumar, Balasubrahmanyam; Philpott, Carl et al.

56 p. 2019, Supplementary Materials.

Research output: Other contribution

TY - GEN

T1 - Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

AU - Khwaja, Sadie

AU - Kumar, Balasubrahmanyam

AU - Philpott, Carl

AU - Strachan, David P.

PY - 2019/11

Y1 - 2019/11

U2 - 10.1016/S0140-6736(19)31881-1

DO - 10.1016/S0140-6736(19)31881-1

M3 - Other contribution

ER -